Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009

Lancet Oncol. 2009 Nov;10(11):1111-8. doi: 10.1016/S1470-2045(09)70241-4.

Abstract

Asia has a disproportionately large share of the world's hepatocellular carcinoma (HCC), mainly because of the endemic status of chronic hepatitis B and C viruses, which leads to liver cirrhosis and an increased risk of HCC. This etiological factor presents important opportunities for prevention, early detection, diagnosis, and treatment of HCC. This consensus statement reviews the available medical evidence for management of HCC in Asia, and gives treatment recommendations that are adapted to resource availability in this diverse region with disparate health-care delivery systems.

Publication types

  • Practice Guideline
  • Review

MeSH terms

  • Antineoplastic Agents / economics
  • Antineoplastic Agents / therapeutic use*
  • Antiviral Agents / therapeutic use
  • Asia / epidemiology
  • Carcinoma, Hepatocellular / diagnosis
  • Carcinoma, Hepatocellular / economics
  • Carcinoma, Hepatocellular / mortality
  • Carcinoma, Hepatocellular / prevention & control
  • Carcinoma, Hepatocellular / therapy*
  • Carcinoma, Hepatocellular / virology
  • Catheter Ablation
  • Chemoembolization, Therapeutic
  • Chemotherapy, Adjuvant
  • Congresses as Topic
  • Cost-Benefit Analysis
  • Developing Countries* / economics
  • Digestive System Surgical Procedures* / economics
  • Drug Costs
  • Early Detection of Cancer
  • Evidence-Based Medicine
  • Guideline Adherence
  • Health Care Costs
  • Health Services Accessibility
  • Healthcare Disparities
  • Hepatectomy
  • Hepatitis B Vaccines / therapeutic use
  • Hepatitis B, Chronic / complications
  • Hepatitis B, Chronic / drug therapy
  • Hepatitis B, Chronic / prevention & control
  • Hepatitis C, Chronic / complications
  • Hepatitis C, Chronic / drug therapy
  • Hepatitis C, Chronic / prevention & control
  • Humans
  • Liver Neoplasms / diagnosis
  • Liver Neoplasms / economics
  • Liver Neoplasms / mortality
  • Liver Neoplasms / prevention & control
  • Liver Neoplasms / therapy*
  • Liver Neoplasms / virology
  • Liver Transplantation
  • Medical Oncology* / economics
  • Medical Oncology* / standards
  • Neoadjuvant Therapy
  • Neoplasm Staging
  • Predictive Value of Tests
  • Preventive Health Services* / economics
  • Radiotherapy, Adjuvant
  • Risk Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Antiviral Agents
  • Hepatitis B Vaccines